RESUMEN
OBJECTIVE: To study the prevalence and the associated factors of work disability (WD) in systemic lupus erythematosus (SLE) patients. METHODS: A sample of 419 SLE patients from an observational cross-sectional multicenter study was included. Sociodemographic features, disease characteristics, comorbidities, quality of life, unhealthy behaviors, and work-related factors were measured in a standardized interview. Work disability was defined by patient self-report of not being able to work because of SLE. To identify variables associated with work disability, two different multivariate regression models using a stepwise backward method were performed. RESULTS: Prevalence of WD due to SLE was 24.3%. Eighty-nine percent were female and 51% were Caucasians. Mean disease duration was 8.9 ± 7.2 years, and median System Lupus International Collaborating Clinics/American College of Rheumatology damage index SLICC-SDI was 1.5 (range 0-17). In stepwise multivariate logistic regression, living below the poverty line (odds ratio [OR] = 4.65), less than 12 years of education (OR = 2.84), Mestizo ethnicity (OR = 1.94) and SLICC-SDI (OR = 1.25) were predictors of WD. A second model was performed including patient-derived measures; in this model sedentary lifestyle (OR = 2.69) and lower emotional health domain score of the Lupus Quality of Life (LupusQoL) questionnaire (OR = 1.03) were found to be associated to WD and a higher score in LupusQoL physical health domain (OR = 0.93) was protective. CONCLUSION: The prevalence of WD in Argentinian SLE patients was 24.3%. WD was associated with ethnic (Mestizo), socioeconomic (poverty) and disease-related factors. Patient-related outcomes such us sedentary lifestyle and poor emotional quality of life were also associated with WD.
Asunto(s)
Absentismo , Evaluación de la Discapacidad , Indígenas Sudamericanos , Lupus Eritematoso Sistémico/etnología , Ausencia por Enfermedad , Determinantes Sociales de la Salud , Factores Socioeconómicos , Adulto , Argentina/epidemiología , Estudios Transversales , Emociones , Femenino , Estado de Salud , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/psicología , Lupus Eritematoso Sistémico/terapia , Masculino , Salud Mental , Persona de Mediana Edad , Pobreza , Prevalencia , Calidad de Vida , Factores de Riesgo , Conducta Sedentaria , Adulto JovenRESUMEN
OBJECTIVE: To define whether Amerindian genetic ancestry correlates with clinical and therapeutic variables in admixed individuals with rheumatoid arthritis (RA) from Latin America. METHODS: Patients with RA (n = 1347) and healthy controls (n = 1012) from Argentina, Mexico, Chile, and Peru were included. Samples were genotyped for the Immunochip v1 using the Illumina platform. Clinical data were obtained through interviews or the clinical history. RESULTS: Percentage of Amerindian ancestry was comparable between cases and controls. Morning stiffness (p < 0.0001, OR 0.05), rheumatoid factor (RF; p < 0.0001, OR 0.22), radiographic changes (p < 0.0001, OR 0.05), and higher number of criteria were associated with lower Amerindian ancestry after Bonferroni correction. Higher Amerindian ancestry correlated only with weight loss (pBonferroni < 0.0001, OR 2.85). Increased Amerindian ancestry correlated with higher doses of azathioprine (p < 0.0001, OR 163.6) and sulfasalazine (p < 0.0001, OR 48.6), and inversely with methotrexate (p = 0.001, OR 0.35), leflunomide (p = 0.001, OR 0.16), and nonsteroidal antiinflammatory drugs (pBonferroni = 0.001, OR 0.37). Only the presence of RF and weight loss were modified after confounders adjustment. CONCLUSION: Amerindian ancestry protects against most major clinical criteria of RA, but regarding the association of RF with increased European ancestry, age, sex, and smoking are modifiers. Ancestry also correlates with the therapeutic profiles.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Reumatoide/genética , Genotipo , Factor Reumatoide/genética , Adulto , Factores de Edad , Anciano , Alelos , Argentina , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/tratamiento farmacológico , Chile , Femenino , Humanos , Indígenas Norteamericanos , Indígenas Sudamericanos , Isoxazoles/uso terapéutico , Leflunamida , Masculino , Metotrexato/uso terapéutico , México , Persona de Mediana Edad , Perú , Radiografía , Factores Sexuales , Sulfasalazina/uso terapéuticoRESUMEN
To determine the prevalence of and associated factors to work instability (WI) in rheumatoid arthritis (RA) Argentinean patients. Observational cross-sectional study that assessing employment status in currently working RA patients. They answered the validated version of RA work instability scale (RA-WIS). High-risk WI was considered when RA-WIS was ≥17. Factors associated with high-risk WI were examined by univariable and multivariable analysis. Four-hundred and fifty RA patients were enrolled; of these, 205 patients were currently employed, but only 172 have completed questionnaires required [RA-WIS and health assessment questionnaire (HAQ-A)]. Their mean age was 49.3 ± 10.8 years; 81.3 % were female; and their mean disease duration was 8.1 ± 7.2 years. Fifty-two percent of patients were doing manual work. The mean RA-WIS score was 11.4 ± 6.8, and 41 % of patients had a high-risk WI. High-risk WI was associated with radiographic erosions (p < 0.001) and HAQ-A >0.87 (p < 0.001) in the univariable analysis, whereas in the multivariable logistic regression analysis the variables associated with a high-risk WI were as follows: HAQ-A >0.87 [odds ratio (OR) 12.31; 95 % CI 5.38-28.18] and the presence of radiographic erosions (OR 4.848; 95 % CI 2.22-10.5). In this model, having a higher monthly income (OR 0.301; 95 % CI 0.096-0.943) and a better functional class (OR 0.151; 95 % CI 0.036-0.632) were protective. Forty-one percent of RA working patients had high-risk WI. The predictors of high RA-WIS were HAQ-A ≥0.87 and radiographic erosions, whereas having a better functional class and have higher incomes were protective.
Asunto(s)
Artritis Reumatoide , Evaluación de la Discapacidad , Empleo , Adulto , Argentina , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To identify susceptibility loci for rheumatoid arthritis (RA) in Latin American individuals with admixed European and Amerindian genetic ancestry. METHODS: Genotyping was performed in 1,475 patients with RA and 1,213 control subjects, using a customized BeadArray containing 196,524 markers covering loci previously associated with various autoimmune diseases. Principal components analysis (EigenSoft package) and Structure software were used to identify outliers and define the population substructure. REAP software was used to define cryptic relatedness and duplicates, and genetic association analyses were conducted using Plink statistical software. RESULTS: A strong genetic association between RA and the major histocompatibility complex region was observed, localized within BTNL2/DRA-DQB1- DQA2 (P = 7.6 × 10(-10) ), with 3 independent effects. We identified an association in the PLCH2-HES5-TNFRSF14-MMEL1 region of chromosome 1 (P = 9.77 × 10(-6) ), which was previously reported in Europeans, Asians, and Native Canadians. We identified one novel putative association in ENOX1 on chromosome 13 (P = 3.24 × 10(-7) ). Previously reported associations were observed in the current study, including PTPN22, SPRED2, STAT4, IRF5, CCL21, and IL2RA, although the significance was relatively moderate. Adjustment for Amerindian ancestry improved the association of a novel locus in chromosome 12 at C12orf30 (NAA25) (P = 3.9 × 10(-6) ). Associations with the HLA region, SPRED2, and PTPN22 improved in individuals positive for anti-cyclic citrullinated peptide antibodies. CONCLUSION: Our data define, for the first time, the contribution of Amerindian ancestry to the genetic architecture of RA in an admixed Latin American population by confirming the role of the HLA region and supporting the association with a locus in chromosome 1. In addition, we provide data for novel putative loci in chromosomes 12 and 13.
Asunto(s)
Artritis Reumatoide/genética , Cromosomas Humanos Par 12/genética , Cromosomas Humanos Par 13/genética , Cromosomas Humanos Par 1/genética , Antígenos HLA/genética , Femenino , Genotipo , Humanos , Indígenas Sudamericanos , América Latina , Masculino , Análisis de Secuencia por Matrices de OligonucleótidosRESUMEN
Introducción: Al igual que en otras enfermedades crónicas, la adherencia al régimen terapéutico de los pacientes con artritis reumatoidea (AR) es baja (entre 30 y 80%), dependiendo de la definición de adherencia y de la metodología empleada para medirla. En este estudio se propone determinar el nivel de adherencia al tratamiento en pacientes con AR que reciben DMAR biológicas e identificar factores asociados a la falta de cumplimiento a la terapia. Material y métodos: Se realizó un estudio analítico, observacional de corte transversal en donde se incluyeron pacientes consecutivos con AR según criterios de clasificación (ACR87) que se encontraban recibiendo fármacos biológicos para el tratamiento de su enfermedad en los últimos seis meses y que asistieron a la consulta ambulatoria. Para la valoración de la adherencia a DMAR se utilizaron los cuestionarios CQR (Compliance Questionnaire on Rheumatology) y el cuestionario SMAQ (Simplified Medication Adherence Questionnaire). Resultados: Se encuestaron 345 pacientes. Mediante el cuestionario SMAQ se observó una adherencia del 50% (159 pacientes). El Cuestionario CQR tuvo un puntaje mediano de 78 puntos (RIC 67-86). El 47% (147 pacientes) fueron adherentes (CQR >80). Sobre los pacientes incluidos, 151 (48%) refirieron no haber tenido ningún retraso, pérdida o adelanto de la dosis del biológico en los últimos 6 meses de tratamiento. El 52% no adherentes tuvo como causas: 146 (46%) pérdida de al menos una dosis del biológico con una mediana de dosis perdidas de 2 (RIQ: 1-3); 117 (37%) tuvo al menos un retraso en las dosis del biológico y 8 (2%) delantó la dosis. Los factores asociados al no cumplimiento de la terapia biológica fueron el tipo de cobertura médica, que el paciente no haya notado mejoría y la esperanza de una rápida respuesta al tratamiento, y la falta de adherencia a DMAR
Introduction: As in other chronic diseases, adherence to the therapeutic regimen of patients with rheumatoid arthritis (RA) is low (between 30 and 80%), depending on the definition of adherence and the methodology used to measure it. This study aims to determine the level of adherence to treatment in patients with RA who receive biological DMARs and to identify factors associated with non-compliance with therapy. MATERIAL AND METHODS: An observational, cross-sectional, observational study was performed in which consecutive patients with RA according to classification criteria (ACR'87) who were receiving biological drugs for the treatment of their disease in the last six months were included Attended the outpatient appointment. The CQR (Compliance Questionnaire on Rheumatology) and SMAQ (Simplified Medication Adherence Questionnaire) questionnaires were used to assess adherence to DMAR. Results: A total of 345 patients were surveyed. A 50% adherence (159 patients) was observed through the SMAQ questionnaire. The CQR Questionnaire had a median score of 78 points (RIC 67-86). 47% (147 patients) were adherent (CQR> 80). Regarding the patients included, 151 (48%) reported not having had any delay, loss or advancement of the biological dose in the last 6 months of treatment. The 52% of non-adherents had as causes: 146 (46%) loss of at least one dose of the biological with a median of doses lost of 2 (RIQ: 1-3); 117 (37%) had at least one biological dose delay and 8 (2%) delayed the dose. Factors associated with non-compliance with biological therapy were the type of medical coverage, the patient's perceived improvement and the expectation of a rapid response to treatment, and lack of adherence to DMAR.
Asunto(s)
Artritis Reumatoide , Tratamiento BiológicoRESUMEN
Objective. To assess the relationship between work productivity with disease activity, functional capacity, life quality and radiological damage in patients with rheumatoid arthritis (RA). Methods. The study included consecutive employed patients with RA (ACR'87), aged over 18. Demographic, disease-related, and work-related variables were determined. The reduction of work productivity was assessed by WPAI-RA. Results. 90 patients were evaluated, 71% women. Age average is 50 years old, DAS28 4, and RAQoL 12. Median SENS is 18 and HAQ-A 0.87. Mean absenteeism was of 14%, presenting an average of 6.30 work hours wasted weekly. The reduction in performance at work or assistance was of 38.4% and the waste of productivity was of 45%. Assistance correlated with DAS28 (r = 0.446; P < 0.001), HAQ-A (r = 0.545; P < 0.001) and RAQoL (r = 0.475; P < 0.001). Lower total productivity was noticed in higher levels of activity and functional disability. Patients with SENS > 18 showed lower work productivity than those with SENS < 18 (50 versus 34; P = 0.04). In multiple regression analysis, variables associated with reduction of total work productivity were HAQ-A and RAQoL. Conclusion. RA patients with higher disease severity showed higher work productivity compromise.
RESUMEN
The main objective of this study is to determine the prevalence of positive and anergic tuberculin skin test (ppd) in a rheumatoid arthritis cohort of patients (RA) and assess the association among ppd results and clinical and treatment variables. Patients with RA diagnosis were included. The ppd was done by Mantoux method. Positive result was considered when indurations were equal or greater than 5 mm. Anergic reaction was defined when the indurations was 0 mm. We included 105 patients (N = 105). The prevalence of positive ppd was 12.4% (n = 13), while the 87.6% (n = 92) presented a negative result. The 69.5% (n = 73) of the population were anergic to ppd. Patients with negative result received higher steroids dosages than patients with positive ppd (p < 0.04). In the multivariable model, the steroids dosage was a significant and independent predictor of negative ppd (p = 0.021, OR 0.72, 95% CI 0.55-0.95). Anergic and non-anergic patients were separated in groups, and a new analysis was done. The higher dosage of methotrexate was associated to tuberculine anergy (p = 0.025). In the multivariable model, the methotrexate dosage was a significant and independent predictor of tuberculine anergy (p = 0.005, OR 1.14, 95% CIs 1.04-1.24). In conclusion, in our cohort, the prevalence of positive ppd was lower than others studies. Among analyzed variables, the high steroid dose was a significant and independent predictor of negative ppd. The methotrexate treatment and dose were associated with ppd anergy.
Asunto(s)
Antirreumáticos/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Tuberculosis Latente/diagnóstico , Prueba de Tuberculina , Adulto , Anciano , Argentina , Artritis Reumatoide/complicaciones , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/inmunología , Productos Biológicos/administración & dosificación , Estudios Transversales , Femenino , Humanos , Isoxazoles/administración & dosificación , Tuberculosis Latente/complicaciones , Tuberculosis Latente/inmunología , Leflunamida , Modelos Logísticos , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Medición de Riesgo , Factores de Riesgo , Esteroides/administración & dosificación , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
Still's disease is a subset of juvenile idiopathic arthritis (JIA) that usually presents with intermittent fever, rash, and arthritis. Extra-articular flares can occur several years after disease onset. We report two cases of adult Still's disease with myocarditis after several years of being in remission. A 34-year-old Caucasian man with history of systemic juvenile arthritis in remission since age 13 was admitted in hospital with 10 days history of fever, odynophagia, and arthralgias. Chest X-ray and cardiac ultrasound showed cardiac enlargement. An endomyocardial biopsy revealed acute myocarditis. He was treated with methylprednisolone and intravenous gammaglobulin, with improvement of his general condition and cardiac parameters. A 16-year-old Caucasian male patient with history of systemic JIA in remission for the last 7 years was admitted with 7 days history of fever, odynophagia, arthralgias, and myalgias. Two days after admission, he developed chest pain and pericardial rubbing was found on examination. Cardiac ultrasound showed left ventricular dilatation with impaired systolic function, and posterior, inferior and apical-septal wall hypokinesia. Blood test showed elevated creatine phosphokinase levels. He was treated with IV methylprednisolone with normal follow-up cardiac ultrasound. Cardiac involvement in patients with systemic JIA can be the first symptom of disease reactivation, even after many years of disease remission.
Asunto(s)
Miocarditis/etiología , Enfermedad de Still del Adulto/complicaciones , Adolescente , Adulto , Artritis Juvenil/complicaciones , Artritis Juvenil/diagnóstico , Fiebre/etiología , Humanos , Masculino , Miocarditis/diagnóstico , Recurrencia , Enfermedad de Still del Adulto/diagnóstico , Resultado del TratamientoRESUMEN
We report a 65-year-old caucasian male, who presented cryptogenic organizing pneumonia (COP) as first manifestation of rheumatoid arthritis. The patient started with fever, myalgias and progressive dyspnea in October 2004. The chest X-ray (CXR) and high resolution computed tomographic scan (HRCT) showed diffuse alveolar exudates with air bronchogram in both the lungs. An open lung biopsy was done and the histological image was compatible with COP. Six months later, a diagnosis of RA was made. Treatment with oral methotrexate and etanercept was prescribed with improvement in symptoms, physical examination, and laboratory tests. Even though COP after the joint involvement is found more frequently in RA, in rare cases it could be the first manifestation of this illness.
Asunto(s)
Artritis Reumatoide/diagnóstico , Neumonía en Organización Criptogénica/diagnóstico , Anciano , Antirreumáticos/uso terapéutico , Artritis Reumatoide/complicaciones , Artritis Reumatoide/tratamiento farmacológico , Neumonía en Organización Criptogénica/tratamiento farmacológico , Neumonía en Organización Criptogénica/etiología , Diagnóstico Diferencial , Etanercept , Humanos , Inmunoglobulina G/uso terapéutico , Masculino , Metotrexato/uso terapéutico , Radiografía Torácica , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of autoantibodies against intracellular components, the formation of immune complexes, and inflammation in various organs, typically the skin and kidney glomeruli. The etiology of the disease is not well understood but is most likely the result of the interaction between genetic and environmental factors. In order to identify susceptibility loci for SLE, we have performed genome scans with microsatellite markers covering the whole genome in families from Argentina, Italy, and Europe. The results reveal a heterogeneous disease with different susceptibility loci in different family sets. We have found significant linkage to chromosome 17p12-q11 in the Argentine set of families. The maximum LOD score was given by marker D17S1294 in combination with D17S1293, when assuming a dominant inheritance model (Z = 3.88). We also analyzed a repeat in the promoter region of the NOS2A gene, a strong candidate gene in the region, but no association was found. The locus on chromosome 17 has previously been identified in genetic studies of multiple sclerosis families. Several other interesting regions were found at 1p35, 1q31, 3q26, 5p15, 11q23 and 19q13, confirming previously identified loci for SLE or other autoimmune diseases.
Asunto(s)
Cromosomas Humanos Par 17/genética , Predisposición Genética a la Enfermedad , Lupus Eritematoso Sistémico/genética , Adulto , Anciano , Argentina/epidemiología , Mapeo Cromosómico , Europa (Continente)/epidemiología , Femenino , Genotipo , Humanos , Italia/epidemiología , Lupus Eritematoso Sistémico/epidemiología , Masculino , Repeticiones de Microsatélite , Persona de Mediana Edad , Linaje , Regiones Promotoras GenéticasRESUMEN
OBJECTIVE: To assess the safety and efficacy of etoricoxib, a selective cyclo-oxygenase-2 inhibitor, in comparison with indometacin in the treatment of acute gouty arthritis. DESIGN: Randomised, double blind, active comparator controlled trial. SETTING: 43 outpatient study centres in 11 countries. PARTICIPANTS: 142 men and eight women (75 patients per treatment group) aged 18 years or over presenting with clinically diagnosed acute gout within 48 hours of onset. INTERVENTIONS: Etoricoxib 120 mg administered orally once daily versus indometacin 50 mg administered orally three times daily, both for 8 days. MAIN OUTCOME MEASURES: Patients' assessment of pain in the study joint over days 2 to 5 (primary end point); investigators' and patients' global assessments of response to treatment and tenderness of the study joint (key secondary end points). RESULTS: Etoricoxib showed efficacy comparable to indometacin. Patients' assessment of pain in the study joint (0-4 point Likert scale, "no pain" to "extreme pain") over days 2 to 5 showed a least squares mean change from baseline of -1.72 (95% confidence interval -1.90 to -1.55) for etoricoxib and -1.83 (-2.01 to -1.65) for indometacin. The difference between treatment groups met prespecified comparability criteria. All other efficacy end points, including those reflecting reduction in inflammation and analgesia, provided corroborative evidence of comparable efficacy. Significant pain relief was evident at the first measurement, 4 hours after the first dose of treatment. Prespecified safety analyses revealed that drug related adverse experiences occurred significantly less frequently with etoricoxib (22.7%) than with indometacin (46.7%) (P=0.003), although overall adverse experience rates were similar between the two treatment groups. CONCLUSION: Etoricoxib 120 mg once daily provides rapid and effective treatment for acute gouty arthritis comparable to indometacin 50 mg three times daily. Etoricoxib was generally safe and well tolerated in this study.
Asunto(s)
Artritis Gotosa/tratamiento farmacológico , Inhibidores de la Ciclooxigenasa/uso terapéutico , Supresores de la Gota/uso terapéutico , Indometacina/uso terapéutico , Piridinas/uso terapéutico , Sulfonas/uso terapéutico , Enfermedad Aguda , Adulto , Anciano , Inhibidores de la Ciclooxigenasa/efectos adversos , Método Doble Ciego , Etoricoxib , Femenino , Supresores de la Gota/efectos adversos , Humanos , Indometacina/efectos adversos , Masculino , Persona de Mediana Edad , Dolor/prevención & control , Dimensión del Dolor , Piridinas/efectos adversos , Sulfonas/efectos adversos , Resultado del TratamientoRESUMEN
La ciclosporina para microemulsión (cpm) ha sido ampliamente utilizada para el tratamiento de la ar- tritis reumatoidea (AR) con muy buenos resultados sobre la progresión del daño articular según ha sido informado por el grupo de estudio GRISAR1. Para evaluar eficacia, seguridad y tolerabilidad de la cpm en el tratamiento de la AR un grupo local de 12 centros (50 pacientes), realizó un estudio abierto, prospectivo (Neo-Ra-02), de seis meses de seguimiento. Los parámetros considerados para evaluar la eficacia fueron: modificación de la rigidez matutina, pruebas funcionales (índices de HAQ, Ritchie y Lee), de laboratorio y radiológicos (índice de Larsen). Los parámetros usados para evaluar la seguridad fueron: tensión arterial y determinaciones de laboratorio de función renal, hepática y análisis hematológico. Los criterios para la participación de los pacientes fueron: presencia de AR activa (según definición del ACR), estadios anatómicos y funcionales de Steinbrocker del I al III, evolución de la enfermedad no mayor de 5 años, ausencia de historia previa de hipertensión arterial, enfermedad renal o hepática y ausencia de uso de drogas modificadoras de la enfermedad en los dos meses anteriores al estudio. A las 4 semanas del tratamiento se verificó disminución estadísticamente significativa del dolor, rigidez matutina, scores de sensibilidad, entumecimiento articular e índice de Ritchie. No hubo incremento significativo de la creatinina, ni del ácido úrico séricos. Seis casos desarrollaron hipertensión arterial leve. La cpm demostró eficacia con mínima incidencia de efectos adversos (12 por ciento de hipertensión arterial leve) cuando su administración fue en dosis bajas y adecuadamente monitoreada.
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Artritis Reumatoide/tratamiento farmacológico , Ciclosporina/uso terapéutico , Tolerancia a Medicamentos , Artritis Reumatoide/complicaciones , Artritis Reumatoide/diagnóstico , Creatinina/análisis , Ciclosporina/efectos adversos , Emulsiones , Estudios de Seguimiento , Hipertensión/inducido químicamente , Estudios Prospectivos , Resultado del Tratamiento , Ácido Úrico/análisisRESUMEN
La ciclosporina para microemulsión (cpm) ha sido ampliamente utilizada para el tratamiento de la ar- tritis reumatoidea (AR) con muy buenos resultados sobre la progresión del daño articular según ha sido informado por el grupo de estudio GRISAR1. Para evaluar eficacia, seguridad y tolerabilidad de la cpm en el tratamiento de la AR un grupo local de 12 centros (50 pacientes), realizó un estudio abierto, prospectivo (Neo-Ra-02), de seis meses de seguimiento. Los parámetros considerados para evaluar la eficacia fueron: modificación de la rigidez matutina, pruebas funcionales (índices de HAQ, Ritchie y Lee), de laboratorio y radiológicos (índice de Larsen). Los parámetros usados para evaluar la seguridad fueron: tensión arterial y determinaciones de laboratorio de función renal, hepática y análisis hematológico. Los criterios para la participación de los pacientes fueron: presencia de AR activa (según definición del ACR), estadios anatómicos y funcionales de Steinbrocker del I al III, evolución de la enfermedad no mayor de 5 años, ausencia de historia previa de hipertensión arterial, enfermedad renal o hepática y ausencia de uso de drogas modificadoras de la enfermedad en los dos meses anteriores al estudio. A las 4 semanas del tratamiento se verificó disminución estadísticamente significativa del dolor, rigidez matutina, scores de sensibilidad, entumecimiento articular e índice de Ritchie. No hubo incremento significativo de la creatinina, ni del ácido úrico séricos. Seis casos desarrollaron hipertensión arterial leve. La cpm demostró eficacia con mínima incidencia de efectos adversos (12 por ciento de hipertensión arterial leve) cuando su administración fue en dosis bajas y adecuadamente monitoreada. (AU)